Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00537407
Other study ID # Debio 025-HCV-207
Secondary ID DEB025A2207
Status Completed
Phase Phase 2
First received September 28, 2007
Last updated February 12, 2016
Start date September 2007
Est. completion date April 2010

Study information

Verified date February 2016
Source Debiopharm International SA
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.

The current standard of care (SOC) in HCV patients consists of a combination of peg-IFN alpha and ribavirin. Treatment duration and ribavirin dose depend on the genotype treated. Only 40-50% of patients with genotype 1 achieve a sustained viral response (SVR). This study assesses whether Debio 025 administered in combination with peg-IFN alpha 2a and ribavirin can improve the outcome of treatment in this group of patients.


Description:

This is a multicentre, open-label, randomized, 5 arm parallel-group, multiple dose study in 50 chronic hepatitis C virus (HCV) genotype 1 non-responders to standard treatment with peg-IFN alpha (2a or 2b) and ribavirin. The entire study lasts a maximum of 96 weeks and consists of a 48- or 72-week treatment period (according to response). A follow-up visit to assess the sustained viral response (SVR) takes place 24 weeks after treatment cessation, i.e., at study Week 72 or 96, or earlier for discontinued study participants.

There were 2 parts in the treatment period. Part 1 lasted from Day 1 to Day 29 (Weeks 1 to 4); Part 2 lasted from Week 5 to Week 48 or 72.

During Part 1 of treatment (Weeks 1 to 4), participants are randomized to 1 of 5 treatment arms and receive 4 weeks of Debio 025 (alisporivir) monotherapy, Debio 025 combined with standard dose peg-IFNα2a, or 1 of 3 triple therapies combining different doses of Debio 025 with peg-IFNα2a and ribavirin at standard doses.

During Part 2 of treatment (Weeks 5 to 48 or 72), participants receive standard doses of peg-IFNα2a/ribavirin dual therapy for 44 or 68 weeks, depending on their response to treatment. At Week 12, participants who do not achieve ≥ 2 log10 decrease in HCV RNA are withdrawn and considered treatment failures. Participants who have undetectable HCV RNA levels and/or ≥ 2 log10 decrease in HCV RNA continue treatment until Week 24. At Week 24, participants who still have detectable HCV RNA levels are withdrawn and considered treatment failures. Participants with undetectable HCV RNA levels at Weeks 12 and 24 continue treatment until Week 48. At Week 24, "slow responders" (defined as participants with a detectable, but > 2 log10 decrease in HCV RNA levels at Week 12 and undetectable levels at Week 24) are eligible to continue treatment until Week 72.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date April 2010
Est. primary completion date April 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Male and female patients between 18 and 60 years of age.

- Hepatitis B negative and human immunodeficiency virus (HIV) negative.

- Diagnosed with hepatitis C genotype I and not responsive to treatments such as peginterferon alpha-2a or 2b and ribavirin for at least 12 weeks.

- Adequate liver function (Child-Pugh-Turcotte score A) and other laboratory parameters within acceptable range.

- Females may participate only if they cannot become pregnant, i.e., are surgically sterile, post-menopausal, or using 2 reliable contraceptive methods.

- Male patients must be surgically sterile or utilizing a barrier contraceptive method.

- For female patients of child bearing potential, negative pregnancy test within 1 week of first investigational product administration.

Exclusion Criteria:

- Treatment with any investigational drug within 6 months prior to the start of the study.

- Ongoing or recent use of antiviral medication within 1 month before the start of the study.

- A known bad reaction or intolerance to Debio 025, peginterferon alpha-2a, and/or ribavirin.

- Presence or history of any severe related disease.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Debio 025
Debio 025 supplied as a 100 mg/mL oral solution
Peg-IFNa2a
Peg-IFNa2a supplied in 180 µg/0.5 mL prefilled syringes
Ribavirin
Ribavirin supplied as 200 mg tablets

Locations

Country Name City State
United States The Johns Hopkins University School of Medicine Baltimore Maryland
United States Methodist Transplant Physicians Dallas Texas
United States Metropolitan Research Fairfax Virginia
United States University of Florida Gainesville Florida
United States Scripps Clinic Liver Disease Research Center la Jolla California
United States University of Miami Center for Liver Diseases Miami Florida
United States Virginia Mason Medical Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Debiopharm International SA

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E) Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction. Baseline to Day 29 No
Secondary Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C) Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction. Baseline to Day 29 No
Secondary log10 Hepatitis C Virus RNA at Day 29 Hepatitis C virus RNA was quantified in plasma samples using real time polymerase chain reaction. Day 29 No
Secondary Percentage of Participants With a Rapid Viral Response at Day 29 A participant had a rapid viral response if their viral RNA was undetectable (< 10 IU/mL). Day 29 No
Secondary Percentage of Participants With an Early Viral Response at Week 12 A participant had an early viral response if their viral RNA had decreased = 2 log10 at Week 12 compared to Baseline. Baseline to Week 12 No
Secondary Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72) A participant had an end-of-treatment response if their viral RNA was undetectable (< 10 IU/mL). End of treatment (Week 48 or 72) No
Secondary Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96) A participant had a sustained viral response if their viral RNA was undetectable (< 10 IU/mL). 24 weeks after the end of treatment (Week 72 or 96) No
See also
  Status Clinical Trial Phase
Completed NCT01937975 - The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050) Phase 1
Completed NCT03673696 - The Tolerability and Pharmacokinetics Study of HEC74647PA Capsule in Healthy Adult Subjects Phase 1
Completed NCT02250001 - Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C N/A
Completed NCT03088917 - 'Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat'
Completed NCT02207088 - Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease Phase 3
Not yet recruiting NCT02865369 - Regression of Liver Fibrosis After Daclatasvir and Asunaprevir Treatment N/A
Recruiting NCT02638233 - Therapy With Ledipasvir/Sofosbuvir in Patients With Genotype 1 HCV Infection Receiving Opiate Substitution Therapy Phase 4
Not yet recruiting NCT02511496 - Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia N/A
Not yet recruiting NCT01949168 - A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV Phase 2
Completed NCT02788682 - Association of Vitamin D Binding Protein Polymorphisms With Response to HCV Therapy N/A
Completed NCT01439776 - Add Vitamin D With Standard of Care for Chronic Hepatitis C Patients Phase 4
Recruiting NCT01360879 - Assessment of Liver FIBROsis by Real-time Tissue ELASTography in Chronic Liver Disease N/A
Recruiting NCT01360892 - Prediction of Incidence of Liver Cancer by Use of Real-time Tissue Elastography N/A
Completed NCT00968357 - Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed Phase 2
Terminated NCT00962936 - Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection Phase 1/Phase 2
Recruiting NCT00575627 - Pegylated-Interferon and Ribavirin in Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels Phase 4
Recruiting NCT01178749 - Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments N/A
Recruiting NCT00370617 - Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Phase 4
Completed NCT01684787 - Study to Evaluate the Treatment for Chronic Hepatitis C With Normal Transaminases in HIV Positive Patients Phase 4
Active, not recruiting NCT00225537 - 4-Methylumbelliferone as a Treatment for Chronic HBV/HCV Phase 2